**Supplementary Table 1. Description of antibodies markers and Isotypes controls included in T-cells, NK cells and monocytes panels analyzed by multiparametric flow cytometry.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **PANEL** | **Clone** | **Reference****And****Trading house** | **Isotype** | **Reference****And****Trading house** |
| **T-cell Exhaustion** |
| LIVE/DEAD fixable Aqua Blue Dead Cell Stain |  | L34966Life Technologies |  |  |
| CD56-BV510 | NCAM16.2 | 563041BD Biosciences |  |  |
| CD19-BV510 | SJ25C1 | 562947BD Biosciences |  |  |
| CD14-BV510 | MOP9 | 563079BD Biosciences |  |  |
| CD3-APC-Cy7 | SK7 | 557832BD Biosciences |  |  |
| CD4-APC-R700 | RPA-T4 | 564975BD Biosciences |  |  |
| CD45RA-ECD | 2H4 | B49193Beckman Coulter |  |  |
| CD27-PerCP-Cy5.5 | M-T271 | 560612BD Biosciences |  |  |
| CD57-FITC | NC1 | B49188Beckman Coulter |  |  |
| TIM-3-PE | 7D3 | 563422BD Biosciences | Ms IgG1,k PE | 981804Biolegend |
| PD1-BV421 | EH12.1 | 562516BD Biosciences | Ms IgG1,k BV421 | 400158Biolegend |
| LAG-3-Pe-Cy7 | 7H2C65 | 369310Biolegend | Ms IgG1,k PE-Cy7 | 400126Biolegend |
| TIGIT-AF647 | A15153G | 372724Biolegend | Ms IgG2a,k AF647 | 400234Biolegend |
| **T-cell Activation** |
| LIVE/DEAD fixable Aqua Blue Dead Cell Stain |  | L34966Life Technologies |  |  |
| CD56-BV510 | NCAM16.2 | 563041BD Biosciences |  |  |
| CD19-BV510 | SJ25C1 | 562947BD Biosciences |  |  |
| CD14-BV510 | MOP9 | 563079BD Biosciences |  |  |
| CD3-APC-Cy7 | SK7 | 557832BD Biosciences |  |  |
| CD8-PB | RPA-T8 | 344718Biolegend |  |  |
| CD27-PerCP-Cy5.5 | M-T271 | 560612BD Biosciences |  |  |
| HLA-DR-APC | GRB-1 | HLADRA-100TBeckman Coulter |  |  |
| CD154-PeCy7 | 24-31 | 310832Biolegend | Ms IgG1,k PE-Cy7 | 400126Biolegend |
| CD137-PE | 4B4-1 | 555956BD Biosciences | Ms IgG1,k PE | 981804Biolegend |
| CD38-FITC | HB7 | 555459BD Biosciences |  |  |
| **Treg** |
| LIVE/DEAD fixable Aqua Blue Dead Cell Stain |  | L34966Life Technologies |  |  |
| CD3-PerCP-Cy5.5 | SK7 | 332771BD Biosciences |  |  |
| CD4-APC-Cy7 | OKT4 | 317418Biolegend |  |  |
| CD31-AF647 | WM59 | 561654BD Biosciences | Ms IgG1,k AF647 | 400130Biolegend |
| CD127-PeCy7 | R34.34 | A64618Beckman Coulter |  |  |
| CD25-BV421 | 9F10 | 302630Biolegend | Ms IgG1,k BV421 | 400158Biolegend |
| FoxP3-PE | 259D/C7 | 12-4776-42BD Biosciences | Ms IgG1,k PE | 981804Biolegend |
| **NK cells** |
| LIVE/DEAD fixable Aqua Blue Dead Cell Stain |  | L34966Life Technologies |  |  |
| CD3-BV510 | SK7 | 564713BD Biosciences |  |  |
| CD14-BV510 | MOP9 | 563079BD Biosciences |  |  |
| CD19-BV510 | SJ25C1 | 562947BD Biosciences |  |  |
| CD56-APC-Cy7 | NCAM16.2 | 318332Biolegend |  |  |
| CD16-PerCP-Cy5.5 | 3G8 | 560717BD Biosciences |  |  |
| CD57-FITC | NC1 | B49188Beckman Coulter |  |  |
| TIM-3-PE | 7D3 | 563422BD Biosciences | Ms IgG1,k PE | 981804Biolegend |
| HLA-DR-APC | GRB-1 | HLADRA-100TBeckman Coulter |  |  |
| CD158b-PE-Cy7 | DX27 | 339512Biolegend | Ms IgG1,k PE-Cy7 | 400126Biolegend |
| NKG2D-PECF594 | 1D11 | 562498BD Biosciences | Ms IgG1,k PECF594 | 562292BD Biosciences |
| NKG2A-BV421 | 131411 | 747924BD Biosciences | Ms IgG2a,k BV421 | 400260Biolegend |
| **Monocytes** |
| LIVE/DEAD fixable Aqua Blue Dead Cell Stain |  | L34966Life Technologies |  |  |
| CD56-BV510 | NCAM16.2 | 563041BD Biosciences |  |  |
| CD19-BV510 | SJ25C1 | 562947BD Biosciences |  |  |
| CD3-BV510 | SK7 | 564713BD Biosciences |  |  |
| HLA-DR-APC | GRB-1 | HLADRA-100TBeckman Coulter |  |  |
| CD14-APC/Cy7 | MφPg | 557831BD Biosciences |  |  |
| CD16-PerCP-Cy5.5 | 3G8 | 560717BD Biosciences |  |  |
| CD62L-PECF594 | DREG-56 | 562301BD Biosciences | Ms IgG1,k PECF594 | 562292BD Biosciences |
| CD49d-BV421 | 9F10 | 304322Biolegend | Ms IgG1,k BV421 | 400158Biolegend |
| CD163-FITC | GHI-61 | 563697BD Biosciences | Ms IgG1,k FITC | 400110Biolegend |
| CD40-PE/Cy7 | 5C3 | 561215BD Biosciences | Ms IgG1,k PE-Cy7 | 400126Biolegend |
| CD287-PE | 4G6 | MA5-16249Life Technologies | Ms IgG1,k PE | 981804Biolegend |

**Supplementary Table 2. Frequency of total NKs, monocytes, T cells and subset distribution in SARS-CoV2 exposed newborns at baseline and 6 months later and non-exposed newborns.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **UM** | **SCV2+** | ***p-value*** |
|  | **Baseline** | **6 months** | ***p*** **(UM** ***vs*** **Baseline)** | ***p* (Baseline *vs*** **6months)** |
| **T-cells** |
| **%CD4+ total cells** | 16[3-26] | 9[0-28] | 26[7-32] | **0.02** | **<0.01** |
| **%CD31+CD4 T-cells** | 92[78-95] | 91[87-99] | 89[83-91] | 0.43 | **<0.01** |
| **%CD45RA+CD4 T-cells** | 93[87-96] | 93[89-98] | 86[77-93] | 0.20 | **<0.01** |
| **%CD31+CD45RA+CD4 T-cells** | 88[74-92] | 88[83-98] | 85[74-89] | 0.30 | **<0.01** |
| **%CD8+ total cells** | 0.2[0-0.6] | 0.2[0-5] | 0.5[0-1] | 0.91 | **<0.01** |
| **%CD31+CD8 T-cells** | 93[89-97] | 94[83-100] | 86[64-96] | 0.20 | **<0.01** |
| **%CD45RA+CD8 T-cells** | 89[82-96] | 92[73-100] | 81[53-91] | 0.12 | **<0.01** |
| **%CD31+CD45RA+CD8 T-cells** | 84[79-95] | 89[64-100] | 74[52-86] | **0.02** | **<0.01** |
| **%CD4+CD8+ total cells** | 0.2[0-0.6] | 0.1[0-1] | 0.5[0-1] | 0.53 | **<0.01** |
| **NK cells** |
| **%CD56dim total cells** | 15[6-31] | 10[1-25] | 9[2-21] | **0.03** | 0.70 |
| **%CD56high total cells** | 1[0.6-2] | 1[0-2] | 1[0-2] | **0.01** | 0.31 |
| **% CD16high total cells** | 8[2-15] | 4[0-17] | 9[1-12] | 0.05 | 0.70 |
| **%CD56dim NK cells** | 99[94-100] | 99[89-100] | 99[96-100] | 0.06 | 0.21 |
| **%CD56high NK cells** | 8[4-19] | 9[4-27] | 10[3-21] | 0.99 | 0.16 |
| **%CD16high NK cells** | 48[31-73] | 51[8-70] | 65[48-82] | 0.87 | **0.03** |
| **Monocytes** |
| **%Total monocytes** | 5[2-17] | 4[0-10] | 1[0-3] | 0.06 | 0.08 |
| **%CD16negCD14high total cells** | 5[1-16] | 3[0-9] | 0.5[0-2] | 0.05 | **0.02** |
| **%CD16negCD14high monocyte cells** | 89[78-96] | 90[49-97] | 52[32-96] | 0.93 | **0.01** |
| **%CD16dimCD14high total cells** | 0.1[0-1] | 0.1[0-1] | 0.1[0-0.3] | 0.15 | 0.65 |
| **%CD16dimCD14high monocyte cells** | 4[1-5] | 3[1-15] | 11[1-22] | 0.45 | **0.01** |
| **%CD16highCD14dim total cells** | 0.2[0-1] | 0.1[0-1] | 0.3[0-0.8] | **0.03** | 0.24 |
| **%CD16highCD14dim monocyte cells** | 6[0-14] | 3[0-20] | 33[1-61] | 0.5 | **<0.01** |

Values are taken at baseline and 6 months later.Continuous variables are expressed as the medians and interquartile ranges [IQR]. Mann-Whitney U-test was used to compare groups.Wilcoxon test was conducted to compare paired events. The frequency of total cells has been calculated with respect to the pool of live PMBCs. SCV2-M, SARS-CoV2 mothers’ group; UM, Uninfected mothers’ group.P-values <0.05 are highlighted.